Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Eur Heart J Acute Cardiovasc Care ; : 2048872619883619, 2019 Oct 28.
Artigo em Inglês | MEDLINE | ID: mdl-31657616

RESUMO

BACKGROUND: The European Society of Cardiology's 0/1-hour algorithm improves the early triage of patients towards "rule-out" or "rule-in" of non-ST-segment elevation myocardial infarction. The HEART score is a risk stratification tool for patients with undifferentiated chest pain. We sought to evaluate the performance of the European Society of Cardiology 0/1-hour algorithm and the HEART score to evaluate chest pain patients in the emergency department. METHODS: In this prospective study, we applied the European Society of Cardiology 0/1-hour algorithm and the HEART score in 1355 consecutive patients who presented to the emergency department with symptoms suggestive of acute coronary syndrome without ST-segment elevation. Patients were followed for non-ST-segment elevation myocardial infarctions and major adverse cardiac events at 30 days: death, non-ST-segment elevation myocardial infarction, or unplanned coronary revascularization. RESULTS: The European Society of Cardiology 0/1-hour algorithm classified 921 (68.0%) patients as "rule-out" and the HEART score classified 686 (50.6%) patients as "low-risk". The 30-day incidence of non-ST-segment elevation myocardial infarctions was 0.32% in the European Society of Cardiology 0/1-hour algorithm "rule-out" patients versus 0.29% in the HEART score "low-risk" patients (p=0.75). The rate of major adverse cardiac events was 7.7% in the European Society of Cardiology 0/1-hour algorithm "rule-out" patients versus 1.1% in the HEART score "low-risk" patients (p<0.001). CONCLUSION: The European Society of Cardiology 0/1-hour algorithm identified more patients with low risk of non-ST-segment elevation myocardial infarctions at 30 days whereas for major adverse cardiac events, the HEART score had a greater capacity to detect low-risk patients.

2.
J Am Coll Cardiol ; 74(4): 483-494, 2019 Jul 30.
Artigo em Inglês | MEDLINE | ID: mdl-31345421

RESUMO

BACKGROUND: The European Society of Cardiology (ESC) recommends the 0/1-h algorithm for rapid triage of patients with suspected non-ST-segment elevation myocardial infarction (MI). However, its impact on patient management and safety when routinely applied is unknown. OBJECTIVES: This study sought to determine these important real-world outcome data. METHODS: In a prospective international study enrolling patients presenting with acute chest discomfort to the emergency department (ED), the authors assessed the real-world performance of the ESC 0/1-h algorithm using high-sensitivity cardiac troponin T embedded in routine clinical care and its associated 30-day rates of major adverse cardiac events (MACE) (the composite of cardiovascular death and MI). RESULTS: Among 2,296 patients, non-ST-segment elevation MI prevalence was 9.8%. In median, 1-h blood samples were collected 65 min after the 0-h blood draw. Overall, 94% of patients were managed without protocol violations, and 98% of patients triaged toward rule-out did not require additional cardiac investigations including high-sensitivity cardiac troponin T measurements at later time points or coronary computed tomography angiography in the ED. Median ED stay was 2 h and 30 min. The ESC 0/1-h algorithm triaged 62% of patients toward rule-out, and 71% of all patients underwent outpatient management. Proportion of patients with 30-day MACE were 0.2% (95% confidence interval: 03% to 0.5%) in the rule-out group and 0.1% (95% confidence interval: 0% to 0.2%) in outpatients. Very low MACE rates were confirmed in multiple subgroups, including early presenters. CONCLUSIONS: These real-world data document the excellent applicability, short time to ED discharge, and low rate of 30-day MACE associated with the routine clinical use of the ESC 0/1-h algorithm for the management of patients presenting with acute chest discomfort to the ED.

3.
Expert Rev Cardiovasc Ther ; 17(3): 225-235, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30715961

RESUMO

INTRODUCTION: The past few years have given rise to extensive research on an interatrial block and its clinical relevance, mainly its association with supraventricular arrhythmias. In 2015, the authors of this article reviewed the Bayes syndrome for the first time and after three years there has been so much evidence accumulated that it seems reasonable to rewrite an update, based fundamentally on the new findings. Focused on its relationship with cardioembolic strokes, today efforts are being targeted at understanding its pathophysiology, its diagnosis, and its prognostic implications, in order to learn if it should be treated. Areas covered: A non-systematic review of the literature was developed using the Pubmed and Cochrane databases, focusing on randomized clinical trials and large observational studies that evaluated new physiopathological and epidemiological aspects, new clinical scenarios in which it has been assessed and its association with dementia. Finally, those studies that proposed new possible treatments were reviewed. Expert commentary: Interatrial block is not only a predictor of supraventricular arrhythmias, is a subclinical disease that might be considered as a marker of risk for adverse outcomes. Although there is some evidence to suggest that early treatment may be beneficial, potential therapies have yet to be investigated.


Assuntos
Arritmias Cardíacas/fisiopatologia , Átrios do Coração/fisiopatologia , Bloqueio Interatrial/fisiopatologia , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto
4.
Rev. argent. cardiol ; 86(5): 15-24, oct. 2018.
Artigo em Espanhol | LILACS-Express | ID: biblio-1003219

RESUMO

RESUMEN Introducción: El score HEART consiste en una prueba sencilla que fue diseñada para estratificar a los pacientes que consultan al servicio de emergencias por dolor torácico, según su riesgo de presentar un síndrome coronario agudo a corto plazo. Fue creado inicialmente con troponina de cuarta generación, pero el advenimiento de la troponina de alta sensibilidad impuso su incorporación al score y la reevaluación de su comportamiento. Objetivo: Nos propusimos evaluar el comportamiento del score HEART con troponina de alta sensibilidad. Material y métodos: Se realizó un estudio prospectivo que incluyó 1464 pacientes (p) que consultaron al servicio de emergencia por dolor torácico y que tenían electrocardiograma sin elevación del segmento ST. Se evaluó la incidencia de MACE (combinado de infarto agudo de miocardio, muerte y revascularización) a 30 días. Resultados: El índice clasificó 739 pacientes (50,5 %) como de bajo riesgo, 515 pacientes (35,2%) de riesgo intermedio y 210 pacientes (14,3%) de alto riesgo. La incidencia de la combinación de infarto agudo de miocardio, muerte y revascularización fue del 1,35% en el primer grupo; del 20%, en el segundo; y del 71%, en el tercero (long rank test p < 0,001). El área bajo la curva global para la combinación de infarto agudo de miocardio, muerte y revascularización fue de 0,91 (0,89-0,93). Conclusiones: El score HEART que utiliza troponina de alta sensibilidad tiene una gran capacidad para clasificar pacientes con dolor torácico de acuerdo con su riesgo de presentar eventos cardiovasculares en el corto plazo.

5.
Expert Rev Cardiovasc Ther ; 16(7): 501-514, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-29862875

RESUMO

INTRODUCTION: Until recently, vitamin K antagonists (VKA) were the only drugs available for long-term anticoagulation. The use of these drugs is laborious due to their variable pharmacokinetics and pharmacodynamics. The advent of direct oral anticoagulants has produced a paradigm shift due to their low incidence of drug interactions, their stable plasma levels, and their lack of monitoring. Rivaroxaban, a factor Xa inhibitor, has been tested in different clinical scenarios and has proved to be effective and safe, even increasing the scope of the old VKA. Areas covered: A non-systematic review of the literature was conducted using the PubMed and Cochrane databases, focusing on randomized clinical trials and real-world observational studies that evaluated rivaroxaban in patients with atrial fibrillation, venous thromboembolism, and atherosclerotic coronary and peripheral vascular disease. Expert commentary: The role of rivaroxaban keeps expanding into areas that were unimaginable few years ago, in the light of solid evidence that has eliminated old strict paradigms. Nonetheless, it will be necessary to adjust costs and better understand the perceived barriers to its widespread implementation, to get fully acceptation of rivaroxaban for the different clinical conditions that have been suggested.


Assuntos
Inibidores do Fator Xa/uso terapêutico , Rivaroxabana/uso terapêutico , Acidente Vascular Cerebral/prevenção & controle , Administração Oral , Fibrilação Atrial/complicações , Coagulação Sanguínea/efeitos dos fármacos , Fibrinolíticos/uso terapêutico , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Acidente Vascular Cerebral/etiologia , Tromboembolia Venosa/prevenção & controle
6.
Arq. bras. neurocir ; 22(3/4): 76-85, 2003.
Artigo em Português | LILACS | ID: lil-387343

RESUMO

Analisamos os resultados e as complicações do tratamento cirúrgico da hérnia discal lombar em nossas casuísticas anteriormente apresentadas e realizamos uma revisão da literatura sobre esse assunto. Comparando os dados obtidos, esquematizamos informações a serem transmitidas aos pacientes sobre a enfermidade. Realizamos a microdiscectomia (1980-1982), em 46 pacientes: confirmaram-se bons resultados em 85 por cento deles; reoperações ocorreram em 8,7 por cento. Em outra casuística (1990-1991) com 160 pacientes, reoperações ocorreram em 21 casos (13 por cento). Desses 21 pacientes, em apenas 8 realizamos a primeira cirurgia. Encontramos recidiva em 9 (5,6 por cento), operação no espaço errado em 6 (3,7 por cento), fibrose em 3 (1,9 por cento) e hérnia nova (pseudo-recorrência) em 3 (1,9 por cento). Para 27 pacientes submetidos à discectomia a laser (1996-1999), o índice de bons resultados foi de 66,7 por cento. Para se indicar cirurgia, deve haver uma perfeita correlação entre as queixas do paciente, o comprometimento neurológico e o diagnóstico por neuroimagem. Atualmente, há uma tendência a se realizar o tratamento clínico por três meses antes de indicação cirúrgica. A cirurgia é segura e eficaz e, quando os resultados são analisados em longo prazo, são semelhantes aos do tratamento conservador. As complicações mais freqüentes da cirurgia, citadas na literatura, são: recidiva da hérnia, operação no espaço errado, descompressão radicular indadequada, lesão radicular e fibrose. Há casos registrados de óbitos relacionados a discite e lesões vasculares. O nosso propósito ao rever os dados apontados é o de propor que o médico, antes de realizar a cirurgia, peça que se assine um termo de consentimento médico em que consta que o paciente foi informado sobre a enfermidade, sobre a necessidade de cirurgia e quais são os objetivos, as possibilidades de sucesso, complicações e reoperações. Os pacientes orientados com tratamento conservador devem ser informados sobre a natureza da enfermidade e o planejamento do tratamento.


Assuntos
Humanos , Consentimento Livre e Esclarecido , Deslocamento do Disco Intervertebral , Erros Médicos , Complicações Pós-Operatórias
7.
Arq. bras. oftalmol ; 58(6): 473-6, dez. 1995. ilus
Artigo em Português | LILACS | ID: lil-169895

RESUMO

Histiocitose de células de Langerhans (HCL) é uma patologia benigna, geralmente com bom prognóstico. Relatou-se um caso de HCL em uma criança que apresentou apenas comprometimento orbitário, de aparecimento rápido, com quadro clínico de proptose axial, indolor, sem sinais flogísticos. O diagnóstico foi realizado através de imagenologia e biópsia incisional da lesäo, com exame histopatológico. O tratamento foi realizado inicialmente com corticoterapia sistêmica, com posterior introduçäo de quimioterapia. O curso clínico foi favorável


Assuntos
Humanos , Feminino , Criança , Exoftalmia/diagnóstico , Histiocitose de Células de Langerhans/fisiopatologia , Órbita/lesões , Histiocitose de Células de Langerhans/diagnóstico , Histiocitose de Células de Langerhans/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA